The analysis of influence of clinical predictors on the results of treatment with erlotinib in patients with advanced non-small cell lung cancer.
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00052779" target="_blank" >RIV/00216224:14110/11:00052779 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
The analysis of influence of clinical predictors on the results of treatment with erlotinib in patients with advanced non-small cell lung cancer.
Original language description
Erlotinib is a tyrosine-kinase inhibitor (TKI) used for the treatment of patients with non small cell lung cancer (NSCLC) in Czech Republic since 2005. Wide use of erlotinib in patients with NSCLC enables to collect a robust data in Czech Tarceva patients registry, where are recorded all the patients treated with erlotinib in 10 centers of excellence in Czech Rep. Objective of this retrospective analysis is to compare treatment efficacy in the subgroup of patients outside the clinical studies and try tofind factors influencing the treatment effect.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů